Hikma Pharmaceuticals PLC
10Portman Square
London W1H 6AZ

T (0)20 7399 2760
F (0)20 7399 2760
E enquiries@hikma.com

Our approach to access to medicines

Contents

Introduction

Our purpose is to put better health within reach, every day. We do this by using our capabilities and global reach to produce high-quality and more affordable medicines and make them accessible to people who need them. Providing access to medicine is central to our sustainability agenda and we are committed to improving accessibility across our geographies.

Generic pharmaceutical companies play a pivotal role in enhancing global access to medicines by providing high-quality, cost-effective alternatives to brand-name drugs. The manufacture and availability of generic medicines contribute to making essential medications more affordable and consistently available. This facilitates broader access to treatments, alleviates global healthcare disparities and supports the effective management of increasingly prevalent chronic conditions.

We recognise the critical role of pharmaceutical companies in working within the healthcare ecosystem to make the right to high-quality, affordable medicines attainable to all. Our Human Rights Statement affirms our belief in the fundamental human right to the highest attainable standard of health. Our primary role in promoting this right is by contributing to the accessibility and affordability of our medicines and ensuring that we manufacture and package our products in accordance with the highest quality standards, while maintaining the success of our business.

hikma.

Our approach to access to medicines

We work across five broad themes to drive accessibility and ensure we are responsive to the needs and priorities of patients within our markets.

How we measure our performance:

- Number of patients treated.[1]

1. A strong manufacturing presence with investments in capacity and growth.

We operate across multiple geographies and make capital investments in manufacturing infrastructure to enhance our capacity to produce medicines.

How we measure our performance:

- Number of new sites
- Number of site expansions completed
- Capex invested in property and plant equipment
- Percentage of core revenue from new business

2. Prioritising quality in everything we do.

Quality is at the foundation of our operations. Supplying medicines reliably and of the highest quality is our number one priority.

How we measure our performance:

- Good manufacturing practices (GMP) and GMP-related audits at our sites (internal and external)
- Individual case safety reports submission compliance rate
- Aggregate reports submission compliance rate

[1] Source: Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA Analytics Link Q4 2025 for the calendar year 2023, 2024 & 2025, reflecting the estimates of real-world activity. Copyright IQVIA. All rights reserved.
Methodology: Drug-treated patient values are derived by converting disease-specific volume sales for each drug to estimated treated patient numbers, adjusted for dosing, duration and compliance, but not concomitance.

3. Maintaining a broad portfolio and investing in producing complex and differentiated products.

We focus on research and development, strategic partnerships and the development of complex, differentiated products to ensure our product portfolio is aligned with evolving patient needs.

How we measure our performance:

- Number of product submissions, approvals and launches

4. Working with patients, healthcare professionals and other stakeholders to strengthen the healthcare ecosystem

We work with patients, healthcare professionals (HCPs) and others to spread knowledge and raise awareness about disease prevention, treatment and healthy living.

How we measure our performance:

- Number of healthcare professionals engaged

5. Responding to crises and urgent medical situations

We provide aid and relief to vulnerable population segments and patients that are affected by emergency situations.

How we measure our performance:

- Value of medicines donated globally

Governance of access to medicine issues

Oversight of access to medicine issues is held at the Board level, with input from an executive-level Access to Medicine Committee and spearheaded by the core functions that operate globally. The direction set by leadership ultimately ensures that relevant functions across the business such as commercial, operations, R&D, business development and others are aligned with the objective of ensuring high-quality medicines are accessible in our markets to those that need them.

Our ambitions going forward

- Investing in local manufacturing capacity to maintain our strength in reliability of supply and affordability
- Further alignment of our product portfolio with evolving patient needs, focusing on providing differentiated and complex medicines
- Leveraging our R&D capabilities to grow our product portfolio, accelerating time-to-market and supporting the Company's strategic growth ambitions
- Working with policymakers, payers and other stakeholders within the healthcare ecosystem to promote accessibility across social segments
- Supporting organisations and governments in addressing crises, shortage situations and assisting marginalised communities
- Raising awareness about health and disease for both patients and HCPs through engagement and educational activities

Appendix

Our sustainability strategy and framework

Our sustainability framework was developed through the findings of our Double Materiality Assessment (DMA) which was completed in 2025. Our primary sustainability focus is advancing health and wellbeing, within which fall the HSTs that were determined to be most material – Access to Medicine and Product Quality, Patient Safety and Social Responsibility, through which we engage our communities to address prevalent health, education and economic issues where we operate.

hikma.

Impacts Risks and Opportunities related to access to medicines

Our DMA was conducted in line with the Corporate Sustainability Reporting Directive (CSRD) and EFRAG's ESRS guidance. The insights gained from the DMA shape our approach to sustainability and ensure its full alignment with our Company purpose and the priorities of our stakeholders.

Detailed topics	Materiality type	IRO type	IRO description	Value chain location and extent
Sub-topic: Social inclusion of consumers and/or end users Sub-sub-topic: Access to products and services	Double materiality	Impact (positive, actual) Opportunity	Through the manufacture of high-quality, affordable medicines, Hikma is providing patients with access to essential treatments, particularly when addressing unmet needs in underserved markets and demographics. By focusing on the medicines that patients need most across Hikma's global markets, Hikma is able to strengthen its market position and enter new markets.	Own operations and downstream (enterprise-wide and across downstream value chain)
Sub-topic: Personal safety of consumers and/or end-users Sub-sub-topic: Health and safety	Double materiality	Impact (positive, actual) Risk	Hikma leverages the strength of its manufacturing operations to ensure the continuous supply of medicines, while adhering to strict product quality and patient safety standards, supporting positive patient outcomes and positioning Hikma as a leading supplier across its global markets.	Own operations and downstream (enterprise-wide and across downstream value chain)